Syros Pharmaceuticals, Inc.
US ˙ OTCPK ˙ US87184Q2066

Introduction

This page provides a comprehensive analysis of the known insider trading history of Philip A Sharp. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Philip A Sharp has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALNY / Alnylam Pharmaceuticals, Inc. Director 0
US:VIR / Vir Biotechnology, Inc. Director 121,174
US:SYRS / Syros Pharmaceuticals, Inc. Director 17,500
US:BIIB / Biogen Inc. Director 5,975
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Philip A Sharp. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SYRS / Syros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SYRS / Syros Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Sales SYRS / Syros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SYRS / Syros Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Purchases VIR / Vir Biotechnology, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SYRS / Syros Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VIR / Vir Biotechnology, Inc. Insider Trades
Insider Sales VIR / Vir Biotechnology, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SYRS / Syros Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VIR / Vir Biotechnology, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Philip A Sharp as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-24 2025-01-23 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -11,250 0 -100.00 275.00 -3,093,750
2025-01-24 2025-01-23 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 11,250 11,250 131.21 1,476,112 1,476,112
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -516 0 -100.00 156.54 -80,775
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -101 516 -16.37 154.07 -15,561 79,500
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1,906 617 -75.54 153.62 -292,800 94,784
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -915 2,523 -26.61 152.40 -139,446 384,505
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -13,557 3,438 -79.77 151.43 -2,052,937 520,616
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -13,005 16,995 -43.35 150.60 -1,958,553 2,559,447
2024-03-01 2024-02-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 30,000 30,000 59.25 1,777,500 1,777,500
2023-05-24 2023-05-22 4 VIR Vir Biotechnology, Inc.
Common Stock
A - Award 6,027 121,174 5.23
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -715 0 -100.00 232.81 -166,459
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -3,853 715 -84.35 231.65 -892,547 165,630
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -16,186 4,568 -77.99 230.71 -3,734,272 1,053,883
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -11,600 20,754 -35.85 229.93 -2,667,188 4,771,967
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1,218 32,354 -3.63 228.33 -278,106 7,387,389
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -98 33,572 -0.29 226.16 -22,164 7,592,644
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 3,670 33,670 12.23 63.86 234,366 2,150,166
2022-08-17 2022-08-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 30,000 30,000 30.09 902,700 902,700
2022-05-25 2022-05-23 4 VIR Vir Biotechnology, Inc.
Stock Option (Right to Buy)
A - Award 12,810 12,810
2022-05-25 2022-05-23 4 VIR Vir Biotechnology, Inc.
Common Stock
A - Award 6,405 115,147 5.89
2022-05-20 2022-05-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,153 5,153
2022-02-11 2022-02-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -30,000 0 -100.00
2022-02-11 2022-02-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -30,000 0 -100.00 150.00 -4,500,000
2022-02-11 2022-02-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 30,000 30,000 11.33 339,900 339,900
2021-07-19 2021-07-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 4,032 4,032
2021-06-10 2021-06-08 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,500 17,500
2021-05-25 2021-05-21 4 VIR Vir Biotechnology, Inc.
Stock Option (Right to Buy)
A - Award 6,748 6,748
2021-05-25 2021-05-21 4 VIR Vir Biotechnology, Inc.
Common Stock
A - Award 3,374 108,742 3.20
2020-12-22 2020-12-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
G - Gift 235,633 266,899 753.64
2020-12-22 2020-12-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
G - Gift -235,633 0 -100.00
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -30,000 0 -100.00
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -645 235,633 -0.27 127.44 -82,199 30,029,070
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2,117 236,278 -0.89 126.16 -267,081 29,808,832
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -15,715 238,395 -6.18 125.05 -1,965,161 29,811,295
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -11,523 254,110 -4.34 124.30 -1,432,309 31,585,873
2020-11-30 2020-11-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 30,000 265,633 12.73 9.30 279,000 2,470,387
2020-10-13 2020-05-21 4/A VIR Vir Biotechnology, Inc.
Stock Option (Right to Buy)
A - Award 24,850 24,850
2020-07-06 2020-07-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 4,581 4,581
2020-06-11 2020-06-11 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,500 17,500
2020-05-26 2020-05-21 4 VIR Vir Biotechnology, Inc.
Stock Option (Right to Buy)
A - Award 28,888 28,888
2020-02-13 2020-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2020-02-13 2020-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2020-02-13 2020-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -30,000 235,633 -11.29 130.00 -3,900,000 30,632,290
2020-02-13 2020-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 265,633 5.98 9.14 137,100 2,427,886
2020-02-13 2020-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 250,633 6.37 15.82 237,300 3,965,014
2019-11-20 2019-11-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2019-11-20 2019-11-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -810 235,633 -0.34 92.66 -75,055 21,833,754
2019-11-20 2019-11-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -8,631 236,443 -3.52 91.97 -793,793 21,745,663
2019-11-20 2019-11-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -5,559 245,074 -2.22 91.17 -506,814 22,343,397
2019-11-20 2019-11-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 250,633 6.37 16.43 246,450 4,117,900
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -44,444 0 -100.00
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -44,444 0 -100.00
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -44,444 0 -100.00
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -88,888 0 -100.00
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Common Stock
C - Conversion 44,444 44,444
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Common Stock
C - Conversion 44,444 44,444
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Common Stock
C - Conversion 44,444 44,444
2019-10-18 2019-10-16 4 VIR Vir Biotechnology, Inc.
Common Stock
C - Conversion 88,888 105,368 539.37
2019-10-11 2019-10-10 4 VIR Vir Biotechnology, Inc.
Stock Option (Right to Buy)
A - Award 22,222 22,222
2019-10-10 3 VIR Vir Biotechnology, Inc.
Common Stock
32,960
2019-10-10 3 VIR Vir Biotechnology, Inc.
Common Stock
32,960
2019-10-10 3 VIR Vir Biotechnology, Inc.
Common Stock
32,960
2019-07-02 2019-07-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,000 9,000
2019-06-12 2019-06-11 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -600 235,633 -0.25 91.40 -54,840 21,536,856
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -400 236,233 -0.17 89.97 -35,988 21,253,883
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2,200 236,633 -0.92 89.03 -195,866 21,067,436
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -11,800 238,833 -4.71 87.86 -1,036,748 20,983,867
2019-04-17 2019-04-15 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 250,633 6.37 22.09 331,350 5,536,483
2018-06-22 2018-06-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 9,000 9,000
2018-06-15 2018-06-14 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -15,000 140,795 -9.63 149.00 -2,235,000 20,978,455
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 155,795 10.65 21.35 320,250 3,326,223
2018-03-13 2018-03-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2018-03-13 2018-03-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -15,000 140,795 -9.63 129.00 -1,935,000 18,162,555
2018-03-13 2018-03-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 155,795 10.65 27.28 409,200 4,250,088
2017-09-22 2017-06-08 4/A SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2017-06-12 2017-06-08 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2017-06-06 2017-06-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 11,250 11,250
2017-02-03 2017-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -25,000 0 -100.00
2017-02-03 2017-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -4,829 140,795 -3.32 40.16 -193,933 5,654,327
2017-02-03 2017-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -20,171 145,624 -12.17 39.72 -801,192 5,784,185
2017-02-03 2017-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 25,000 165,795 17.76 31.29 782,250 5,187,726
2017-01-27 2017-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2017-01-27 2017-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -15,000 140,795 -9.63 37.95 -569,250 5,343,170
2017-01-27 2017-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 155,795 10.65 31.39 470,850 4,890,405
2017-01-20 2017-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -15,000 0 -100.00
2017-01-20 2017-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6,200 140,795 -4.22 38.20 -236,840 5,378,369
2017-01-20 2017-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -8,800 146,995 -5.65 37.57 -330,616 5,522,602
2017-01-20 2017-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 15,000 155,795 10.65 15.91 238,650 2,478,698
2016-09-19 2016-09-15 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 22,000 22,000
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -150,000 0 -100.00
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -150,000 0 -100.00
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -150,000 0 -100.00
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -550,000 0 -100.00
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 40,000 40,000
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 40,000 40,000
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 40,000 40,000
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 146,666 146,666
2016-06-07 2016-06-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 11,250 11,250
2015-12-04 2015-12-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10,000 0 -100.00
2015-12-04 2015-12-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Non-Qualified Stock Option (right to buy)
M - Exercise X -20,000 0 -100.00
2015-12-04 2015-12-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -30,000 140,795 -17.56 109.00 -3,270,000 15,346,655
2015-12-04 2015-12-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 20,000 170,795 13.26 14.05 281,000 2,399,670
2015-12-04 2015-12-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10,000 150,795 7.10 14.74 147,400 2,222,718
2015-06-03 2015-06-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 11,250 11,250
2015-06-03 2015-06-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other -25,844 126,104 -17.01
2015-06-03 2015-06-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 25,844 140,795 22.48
2014-10-15 2014-10-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -100,000 0 -100.00
2014-10-15 2014-10-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10,000 0 -100.00
2014-10-15 2014-10-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -110,000 74,996 -59.46 85.00 -9,350,000 6,374,660
2014-10-15 2014-10-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10,000 184,996 5.71 7.08 70,800 1,309,772
2014-10-15 2014-10-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 100,000 174,996 133.34 7.77 777,000 1,359,719
2014-10-15 2014-07-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other -21,890 191,903 -10.24
2014-10-15 2014-07-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 21,890 74,996 41.22
2014-06-06 2014-06-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 30,000 30,000
2014-01-03 2014-01-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 3,670 3,670
2014-01-03 2013-07-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other -11,512 213,793 -5.11
2014-01-03 2013-07-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other -27,325 225,305 -10.82
2014-01-03 2013-07-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 11,512 53,106 27.68
2014-01-03 2013-07-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 27,325 41,594 191.50
2013-06-10 2013-06-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 30,000 30,000
2013-01-24 2013-01-22 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
P - Purchase 4,967 14,269 53.40 20.13 99,986 287,235
2012-06-25 2012-06-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 30,000 30,000
2012-02-23 2012-02-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
P - Purchase 9,302 9,302 10.75 99,996 99,996
2011-06-13 2011-06-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 30,000 30,000
2009-06-05 2009-06-03 4 BIIB BIOGEN IDEC INC.
Stock Option (Right to Buy)
A - Award 5,975 5,975
2009-06-05 2009-06-03 4 BIIB BIOGEN IDEC INC.
Common Stock
A - Award 2,245 470,278 0.48
2008-07-09 2008-07-09 4 BIIB BIOGEN IDEC INC.
Stock Option (rignt to buy)
A - Award 5,700 5,700
2008-07-09 2008-07-09 4 BIIB BIOGEN IDEC INC.
Common Stock
A - Award 2,050 468,033 0.44
2007-05-30 2007-05-25 4 BIIB BIOGEN IDEC INC.
Restricted Stock Unit
M - Exercise -1,250 0 -100.00
2007-05-30 2007-05-25 4 BIIB BIOGEN IDEC INC.
Common Stock
M - Exercise 1,250 463,683 0.27
2006-06-02 2006-06-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 10,000 10,000
2006-05-30 2006-05-25 4 BIIB BIOGEN IDEC INC
Restricted Stock Units
A - Award 1,250 1,250
2006-05-30 2006-05-25 4 BIIB BIOGEN IDEC INC
Employee Stock Option (right-to-buy)
A - Award 3,125 3,125
2004-05-27 3 ALNY ALNYLAM PHARMACEUTICALS INC
Common Stock
233,333
2004-05-05 2004-05-05 4 BIIB BIOGEN IDEC INC
Common Stock
S - Sale -50,000 772,100 -6.08 59.00 -2,950,000 45,553,900
2004-05-05 2004-05-04 4 BIIB BIOGEN IDEC INC
Common Stock
S - Sale -5,900 822,100 -0.71 58.90 -347,510 48,421,690
2004-05-05 2004-05-04 4 BIIB BIOGEN IDEC INC
Common Stock
S - Sale -23,000 115,000 -16.67 59.00 -1,357,000 6,785,000
2004-05-05 2004-05-04 4 BIIB BIOGEN IDEC INC
Common Stock
M - Exercise 23,000 138,000 20.00 11.73 269,790 1,618,740
2004-05-05 2004-04-05 4 BIIB BIOGEN IDEC INC
Stock Option (right-to-buy)
M - Exercise -23,000 15,000 -60.53
2003-11-14 3 BIIB BIOGEN IDEC INC
No S ecurities Beneficially owned.
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)